AstraZeneca Makes About $10 Billion Offer for Rhythm Pharmaceuticals
Direct answer
AstraZeneca has offered about $10 billion to buy Rhythm Pharmaceuticals, according to Reuters reporting on November 4, 2026. The offer is non-binding, which means it is a proposal, not a completed deal. Rhythm shares closed up 28 percent on the news.
What happened
Reuters reported that AstraZeneca offered as much as $134 a share, including payments linked to future milestones, according to three people familiar with the matter. The Wall Street Journal had reported earlier on Wednesday that AstraZeneca made a $124 per share offer for the company last month.
Rhythm shares closed up 28 percent at $110.68 on the news, giving the company a market value of about $7.64 billion. The higher headline offer price, at up to $134 a share, helps explain why the market reacted so strongly, even though the proposal is not yet binding.
The deal would be pursued through AstraZeneca’s rare disease business, Alexion, which AstraZeneca bought for $39 billion in 2021 to expand beyond its core cancer and biopharmaceutical work. Rhythm develops therapies for rare neuroendocrine disorders, while Alexion specialises in treatments for rare diseases. That fit is central to the story, because AstraZeneca is looking to expand in high growth specialty medicines.
AstraZeneca also jumped recently for a different reason, as covered in our post on the FTSE 100’s first monthly gain in three months, when a restructuring plan lifted its shares. This offer is a separate event, focused on buying a smaller specialist company rather than cutting costs at home.
Why it matters for beginners
A takeover offer is often a useful lesson in how share prices react to news. When a buyer offers more than the current share price, the target company’s shares usually jump toward, but not all the way to, the offer price. The gap reflects doubt about whether the deal will actually close.
A non-binding offer matters here. It means AstraZeneca has put a proposal on the table, but the terms are not final and the deal could still change or fall apart. Investors priced in excitement, with a 28 percent rise, but not certainty, since the close at $110.68 stayed below the reported offer levels.
For beginners, it is also a reminder that one company can move for many reasons. AstraZeneca rose in October on cost savings, and now Rhythm is rising on a takeover offer. The same company name can appear in very different stories in the same month, so it helps to read what actually changed each time.
What to watch next
First, whether Rhythm confirms the talks or gives its own statement, and whether either company announces a binding agreement. Second, whether the price changes from the reported $124 and $134 per share figures, since milestone payments can make the final value hard to compare. Third, how AstraZeneca shares react, because a large purchase uses cash that could otherwise fund research or returns to shareholders. And fourth, whether regulators or rival bidders get involved, which can delay or reshape a deal of this size.
FAQ
What is a non-binding offer?
It is a proposal to buy a company that is not yet a final, legally binding agreement. The buyer and seller can still negotiate, change terms, or walk away.
Why did Rhythm shares jump 28 percent?
Reuters reported an offer worth about $10 billion, at up to $134 a share including milestone payments, well above where the shares had traded. When a buyer offers a premium, the target’s shares usually rise to reflect that offer, while staying below it until a deal is certain.
What does Alexion have to do with this?
Alexion is AstraZeneca’s rare disease business. Reuters reported the acquisition would be pursued through Alexion, which fits Rhythm’s work on rare disorders and AstraZeneca’s push into specialty medicines.
Does this mean the deal is done?
No. A non-binding proposal is only a step toward a possible deal. Until a binding agreement is announced and completed, the purchase is not certain.
Sources
Reuters, “AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say”, November 4, 2026 Reuters report
The Wall Street Journal, as reported by Reuters on November 4, 2026, on the earlier $124 per share offer.
This article is for general information and education only. It is not legal or financial advice.
